Interview with Emily Y. Chew, MD, author of Lutein + Zeaxanthin and Omega-3 Fatty Acids for Age-Related Macular Degeneration: The Age-Related Eye Disease Study 2 (AREDS2) Randomized Clinical Trial

Interview with Jonas Rutishauser, MD, author of Short-term vs Conventional Glucocorticoid Therapy in Acute Exacerbations of Chronic Obstructive Pulmonary Disease: The REDUCE Randomized Clinical Trial

Interview with Harvey V. Fineberg, MD, PhD, author of The Paradox of Disease Prevention: Celebrated in Principle, Resisted in Practice

Interview with Christopher J. L. Murray, MD, DPhil, author of The State of US Health, 1990-2010: Burden of Diseases, Injuries, and Risk Factors

Interview with Marianna K Baum, PhD, author of Effect of Micronutrient Supplementation on Disease Progression in Asymptomatic, Antiretroviral-Naive, HIV-Infected Adults in Botswana

Interview with Maurice W. Dysken, MD, author of Effect of Vitamin E and Memantine on Functional Decline in Alzheimer Disease: The TEAM-AD VA Cooperative Randomized Trial

Interview with Constantine G. Lyketsos, MD, MHS, author of Effect of Citalopram on Agitation in Alzheimer Disease

Interview with Nynne Nyboe Andersen, MD, author of Association Between Tumor Necrosis Factor-α Antagonists and Risk of Cancer in Patients With Inflammatory Bowel Disease

Interview with George R. Buchanan, MD, author of Management of Sickle Cell Disease

Interview with Andrea S. Gershon, MD, MSc, author of Combination Long-Acting β-Agonists and Inhaled Corticosteroids Compared With Long-Acting β-Agonists Alone in Older Adults With Chronic Obstructive Pulmonary Disease

Interview with Thomas M. Maddox, MD, MSc, author of Nonobstructive Coronary Artery Disease and Risk of Myocardial Infarction

Interview with Frank M. Sacks, MD, author of Effects of High vs Low Glycemic Index of Dietary Carbohydrate on Cardiovascular Disease Risk Factors and Insulin Sensitivity

Interview with Jeffrey L. Cummings, MD, ScD, author of Effect of Dextromethorphan-Quinidine on Agitation in Patients With Alzheimer Disease Dementia: A Randomized Clinical Trial

Edward H. Livingston, MD discusses Graves disease with David Cooper, MD, author of Management of Graves Disease: A Review

Interview with Saad B. Omer, MBBS, MPH, PhD, author of Association Between Vaccine Refusal and Vaccine-Preventable Diseases in the United States A Review of Measles and Pertussis

Interview with William R. Phillips, MD, MPH, author of Screening for Chronic Obstructive Pulmonary Disease: US Preventive Services Task Force Recommendation Statement

Lyme disease is very common in certain regions of the country and is caused by the spirochete Borrelia bergdorferi. Lyme disease is transmitted by tick bites and in this podcast we review the discovery of Lyme disease, its major clinical features, and how to diagnose and treat it, as told by Dr Alan Steere, Dr Lyndon Hu, and Dr Paul Auerwerter.

Related article: Review of Lyme Disease, Human Granulocytic Anaplasmosis, and Babesiosis

Interview with Douglas K. Owens, MD, MS, USPSTF Task Force member and coauthor of Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: US Preventive Services Task Force Recommendation Statement

Interview with Alex H Krist, MD, MPH, Task Force member and co-author of Screening for Celiac Disease: US Preventive Services Task Force Recommendation Statement

Interview with Christopher JL. Murray, MD, DPhil, author of The State of US Health, 1990-2016: Burden of Diseases, Injuries, and Risk Factors Among US States

Interview with Seth Landefeld, MD, Task Force member and co-author of Screening for Cardiovascular Disease Risk With Electrocardiography: US Preventive Services Task Force Recommendation Statement

Interview with Michael J. Barry, MD, Task Force member and co-author of Screening for Peripheral Artery Disease and Cardiovascular Disease Risk Assessment With the Ankle-Brachial Index: US Preventive Services Task Force Recommendation Statement

Interview with Gary H. Gibbons, M.D., author of Accelerating the Science of SCD Therapies—Is a Cure Possible?

Interview with Julia A. Segre, Ph.D., author of Manipulating the Human Microbiome to Manage Disease

Interview with Jenny A. Doust, BMBS, author of Potential Consequences of Changing Disease Classifications

The strategy for managing the COVID-19 pandemic has shifted from containment to mitigation. What does that mean for US hospitals and health systems? Kaiser Permanente Executive Vice President Stephen M. Parodi, MD, discusses telemedicine, protecting health care workers, equipment allocation planning, and more.

Infectious epidemics have always driven change and triggered discrimination in human societies. Frank Snowden, DPhil, Professor Emeritus of History and History of Medicine at Yale University and author of Epidemics and Society: From the Black Death to the Present (Yale University Press, 2019), puts the COVID-19 pandemic in historical context.

Borkar, S. G. (Suresh Govindrao), 1956- author

Patarnello, Pierpaolo, author

Aglave, Balaji, author

Niks, R. E. (Rients Engelhard), 1953- author

Barker Library - TL725.3.M2 A37 2019

Rotch Library - DT116.D48 2019

With the emergence of coronavirus disease 2019 (COVID-19) as a global pandemic, individuals with preexisting chronic health conditions such as hypertension, diabetes, and cardiovascular disease have been identified as particularly vulnerable. These patients are also more likely than the general population to be taking angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs). As the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus that causes COVID-19 gains entry into cells via binding to the angiotensin-converting enzyme 2 (ACE2) receptor, concerns have been raised that these therapies might facilitate the transmission of the virus or affect outcomes adversely. Given that ACEI and ARB therapies are known to provide benefit for the underlying conditions treated, stopping ACEI/ARB therapy carries risks. Moreover, local inactivation of the renin-angiotensin-aldosterone system may have protective effects against the development and progression of acute lung failure. In the absence of clinical evidence of benefit or risk of ACEIs/ARBs, current societal statements recommend against discontinuing these drugs other than for standard clinical indications. Robust clinical data are needed to clarify the effect of ACEIs/ARBs on SARS-CoV-2 infection.